An adjustable predictive score of graft survival in kidney transplant patients and the levels of risk linked to de novo donor-specific anti-HLA antibodies

被引:15
|
作者
Premaud, Aurelie [1 ,2 ]
Filloux, Matthieu [3 ,4 ]
Gatault, Philippe [5 ]
Thierry, Antoine [6 ]
Buchler, Matthias [5 ]
Munteanu, Eliza [7 ]
Marquet, Pierre [1 ,2 ,8 ]
Essig, Marie [1 ,2 ,7 ]
Rousseau, Annick [1 ,2 ]
机构
[1] INSERM, U850, Limoges, France
[2] Univ Limoges, UMR S850, Limoges, France
[3] CHU Limoges, Serv Immunol & Immunogenet, Limoges, France
[4] CNRS, CRIBL, UMR 7276, Limoges, France
[5] CHU Tours, Serv Nephrol & Immunol Clin, Tours, France
[6] CHU Poitiers, Serv Nephrol Hemodialyse Transplantat Renal, Poitiers, France
[7] CHU Limoges, Serv Nephrol, Dialyse Transplantat, Limoges, France
[8] CHU Limoges, Serv Pharmacol Toxicol & Pharmacovigilance, Limoges, France
来源
PLOS ONE | 2017年 / 12卷 / 07期
关键词
RENAL-TRANSPLANTATION; SERUM CREATININE; ALLOGRAFT LOSS; FAILURE; REJECTION; OUTCOMES; FORESTS; SYSTEM; COHORT; TIME;
D O I
10.1371/journal.pone.0180236
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Most predictive models and scores of graft survival in renal transplantation include factors known before transplant or at the end of the first year. They cannot be updated thereafter, even in patients developing donor-specific anti-HLA antibodies and acute rejection. We developed a conditional and adjustable score for prediction of graft failure (AdGFS) up to 10 years post-transplantation in 664 kidney transplant patients. AdGFS was externally validated and calibrated in 896 kidney transplant patients. The final model included five baseline factors (pretransplant non donor-specific anti-HLA antibodies, donor age, serum creatinine measured at 1 year, longitudinal serum creatinine clusters during the first year, proteinuria measured at 1 year), and two predictors updated over time (de novo donor-specific anti-HLA antibodies and first acute rejection). AdGFS was able to stratify patients into four riskgroups, at different post-transplantation times. It showed good discrimination (time-dependent ROC curve at ten years: 0.83 (CI95% 0.76-0.89).
引用
收藏
页数:16
相关论文
共 50 条
  • [21] Posttransplant De Novo Donor-Specific HLA Antibodies Identify Pediatric Kidney Recipients at Risk for Late Antibody-Mediated Rejection
    Ginevri, F.
    Nocera, A.
    Comoli, P.
    Innocente, A.
    Cioni, M.
    Parodi, A.
    Fontana, I.
    Magnasco, A.
    Nocco, A.
    Tagliamacco, A.
    Sementa, A.
    Ceriolo, P.
    Ghio, L.
    Zecca, M.
    Cardillo, M.
    Garibotto, G.
    Ghiggeri, G. M.
    Poli, F.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2012, 12 (12) : 3355 - 3362
  • [22] Impact of Low-Level Donor-Specific Anti-HLA Antibody on Posttransplant Clinical Outcomes in Kidney Transplant Recipients
    Lee, Haeun
    Lee, Hanbi
    Eum, Sang Hun
    Ko, Eun Jeong
    Min, Ji-Won
    Oh, Eun-Jee
    Yang, Chul Woo
    Ha Chung, Byung
    ANNALS OF LABORATORY MEDICINE, 2023, 43 (04) : 364 - 374
  • [23] Liver graft injury caused by de novo donor-specific HLA antibodies in pediatric liver transplant recipients with low, moderate, and high immunologic risk
    Liu, Wei
    Wang, Zheng-Lu
    Kang, Zhong-Yu
    Xiao, Yan-Li
    Liu, Chun
    Li, Dai-Hong
    AMERICAN JOURNAL OF SURGERY, 2023, 225 (02) : 275 - 281
  • [24] Impact of Early Blood Transfusion After Kidney Transplantation on the Incidence of Donor-Specific Anti-HLA Antibodies
    Ferrandiz, I.
    Congy-Jolivet, N.
    Del Bello, A.
    Debiol, B.
    Trebern-Launay, K.
    Esposito, L.
    Milongo, D.
    Dorr, G.
    Rostaing, L.
    Kamar, N.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2016, 16 (09) : 2661 - 2669
  • [25] Effect of SARS-CoV-2 infection on anti-HLA antibodies and de novo donor specific antibodies incidence in lung transplant recipients
    Zajacova, Andrea
    Dvorackova, Eliska
    Casas-Mendez, Luis Fernando
    Vychytilova, Katerina
    Rakita, Dmitry
    Valentova-Bartakova, Lucie
    Svorcova, Monika
    Slavcev, Antonij
    Fila, Libor
    Lischke, Robert
    Havlin, Jan
    TRANSPLANT IMMUNOLOGY, 2023, 81
  • [26] Markers of graft microvascular endothelial injury may identify harmful donor-specific anti-HLA antibodies and predict kidney allograft loss
    Louis, Kevin
    Hertig, Alexandre
    Taupin, Jean-Luc
    Buob, David
    Jamme, Matthieu
    Brocheriou, Isabelle
    Luque, Yosu
    Jouanneau, Chantal
    Ouali, Nacera
    Audouin, Marie
    Rondeau, Eric
    Xu-Dubois, Yi-Chun
    AMERICAN JOURNAL OF TRANSPLANTATION, 2019, 19 (09) : 2434 - 2445
  • [27] Development and outcomes of de novo donor-specific antibodies in low, moderate, and high immunological risk kidney transplant recipients
    Wan, Susan S.
    Chadban, Steven J.
    Watson, Narelle
    Wyburn, Kate
    AMERICAN JOURNAL OF TRANSPLANTATION, 2020, 20 (05) : 1351 - 1364
  • [28] Analysis of preformed donor-specific anti-HLA antibodies characteristics for prediction of antibody-mediated rejection in kidney transplantation
    Malheiro, Jorge
    Tafulo, Sandra
    Dias, Leonidio
    Martins, La Salete
    Fonseca, Isabel
    Beirao, Idalina
    Castro-Henriques, Antonio
    Cabrita, Antonio
    TRANSPLANT IMMUNOLOGY, 2015, 32 (02) : 66 - 71
  • [29] Incidence of Donor-Specific Anti-HLA Antibodies in Non-HLA-Sensitized Patients Given Tacrolimus Once or Twice Daily During the First 2 Years After Kidney Transplant
    Hage, Valerie
    Ferrandiz, Ines
    Belliere, Julie
    Esposito, Laure
    Hebral, Anne Laure
    Cointault, Olivier
    Del Bello, Arnaud
    Kamar, Nassim
    EXPERIMENTAL AND CLINICAL TRANSPLANTATION, 2019, 17 (03) : 313 - 319
  • [30] Deleterious effect of anti-angiotensin II type 1 receptor antibodies detected pretransplant on kidney graft outcomes is both proper and synergistic with donor-specific anti-HLA antibodies
    Malheiro, Jorge
    Tafulo, Sandra
    Dias, Leonidio
    Martins, La Salete
    Fonseca, Isabel
    Beirao, Idalina
    Castro-Henriques, Antonio
    Cabrita, Antonio
    NEPHROLOGY, 2019, 24 (03) : 347 - 356